single5MG
GHRP-6
5MG Protocol
GHRP-6 5MG
Injection Freq.
Inject three times daily
Cycle Sched.
8–12 weeks; rotate injection sites to prevent tissue irritation
Reconstitution
3.0 mL BAC water
Supports lean-mass gain and fat reduction via GH/IGF-1 signaling
Improved recovery and sleep architecture (more slow-wave sleep described)
Appetite stimulation (may aid weight-gain goals)
Cytoprotective/tissue-protective effects in preclinical models
Joint/connective-tissue support via collagen and repair signaling
1
Reconstitution Requirements
- 3.0 mL BAC water
| Step | Week Range | Dose | Units |
|---|---|---|---|
| 1 | Weeks 1–2 | 100 mcg | 6 |
| 2 | Weeks 3–4 | 200 mcg | 12 |
| 3 | Weeks 5–12 | 300 mcg | 18 |
Inject three times daily
8–12 weeks; rotate injection sites to prevent tissue irritation
GHRP-6 is characterized as a ghrelin-receptor agonist (GHS-R1a) that produces rapid, pulsatile growth hormone secretion while reducing somatostatin inhibition. Because the stimulus is upstream and episodic, the protocol describes maintained physiologic feedback control as GH/IGF-1 rise, which can help keep pulses within a normal range rather than creating continuous hormone exposure. A second mechanistic layer is attributed to CD36 receptor engagement on immune and muscle cells, where downstream signaling (including PI3K/Akt) may support cellular survival under oxidative stress and inflammatory challenge. This combination—endocrine pulse stimulation plus CD36-linked cytoprotection—is used to explain the compound’s reported range of research observations (body composition, recovery, and tissue protection). In summary, the peptide is presented as a dual-pathway secretagogue with both hormonal and tissue-resilience signaling components.
Transient mild increases in cortisol/ACTH
Increased appetite
Water retention
Injection-site reactions (redness/itching/swelling)
Transient dizziness or flushing shortly after injection
- Use aseptic technique: wipe vial stopper with alcohol; use new sterile syringe/needle
- Add diluent slowly down the vial wall to minimize foaming
- Gently swirl/roll until fully dissolved (do not shake)
- Label vial with reconstitution date and concentration; protect from light
- Refrigerate after reconstitution (commonly 2–8 °C) unless protocol states otherwise
- Avoid repeated freeze–thaw cycles
- Bacteriostatic Water for Injection contains benzyl alcohol preservative (multi-dose); follow protocol for beyond-use (many peptide protocols use ~28 days after mixing)
- Avoid benzyl-alcohol-containing diluents in neonates/infants (safety warning for benzyl alcohol)